SCHEMBL3562679

SCHEMBL3562679

Cc1nn(-c2ccc(Sc3cccc(C4(C#N)CCOCC4)c3)cc2)c(=O)n1C1CCCC1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 5/20 0.42
CTSK P43235 1/20 0.36
PIK3CD O00329 2/20 0.35
TRPV4 Q9HBA0 2/20 0.34
DHODH Q02127 2/20 0.32
PRKDC P78527 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
PIK3CA P42336 1/20 0.31
LRRK2 Q5S007 1/20 0.31
PDE1A P54750 1/20 0.30
PDE1B Q01064 1/20 0.30
PDE1C Q14123 1/20 0.30
TNF P01375 1/20 0.30
LITAF Q99732 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3569264 0.99 ALOX5 (0.41) ALOX5CTSKPIK3CDTRPV4DHODH
SCHEMBL3569405 0.99 ALOX5 (0.41) ALOX5CTSKPIK3CDTRPV4DHODH
SCHEMBL3571358 0.86 ALOX5 (0.40) ALOX5PIK3CDTRPV4DHODHPDE4A
SCHEMBL3570959 0.86 ALOX5 (0.47) ALOX5CTSKPIK3CDPIK3CAPDE1A
SCHEMBL3577081 0.85 ALOX5 (0.61) ALOX5CTSKPIK3CDDHODHPDE4A
SCHEMBL3568598 0.85 ALOX5 (0.42) ALOX5PIK3CDDHODHPDE1APDE1B
SCHEMBL3560392 0.84 ALOX5 (0.60) ALOX5PIK3CDDHODHPDE4APDE4B
SCHEMBL3568520 0.83 ALOX5 (0.43) ALOX5PIK3CDTRPV4DHODHPDE1A
SCHEMBL3568405 0.83 ALOX5 (0.43) ALOX5CTSKPIK3CDPDE1APDE1B
SCHEMBL3575020 0.83 ALOX5 (0.43) ALOX5CTSKPIK3CDPDE1APDE1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674811-B2 5-lipoxygenase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2010-03-09 US claimed
US-20080021080-A1 5-LIPOXYGENASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2008-01-24 US claimed
EP-1834953-A1 Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors Ranbaxy Laboratories Limited (IN) 2007-09-19 EP claimed
US-7674811-B2 5-lipoxygenase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2010-03-09 US disclosed
US-20080021080-A1 5-LIPOXYGENASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2008-01-24 US disclosed
EP-1834953-A1 Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors Ranbaxy Laboratories Limited (IN) 2007-09-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021080-A1 5-LIPOXYGENASE INHIBITORS ALOX5, ALOX15B, ALOX15 ALOX5 1/4885CTSK 1763/4885PIK3CD 2405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.